Methods and compositions for treating melanoma
US-2024424002-A1 · Dec 26, 2024 · US
Pharmaceutical compositions directly targeting FKBP52 for the treatment of prostate cancer and methods of using same
US10322113B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10322113-B2 |
| Application number | US-201515504562-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 20, 2015 |
| Priority date | Aug 20, 2014 |
| Publication date | Jun 18, 2019 |
| Grant date | Jun 18, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Embodiments of the current invention include methods and compositions for regulating the activity of hormone receptors.
First claim
Opening claim text (preview).
The invention claimed is: 1. An FKBP52 binding molecule having a chemical structure of Formula II wherein R 1 or R 2 are independently and separately selected from H, amino, nitro, halogen, F 5 S, F 3 C, or C1-C3 alkoxy, wherein R 1 and R 2 are not both H; R 3 is independently selected from H or C1-C3 alkyl; R 4 is independently selected from H, C1-C3 alkyl, C1-C3 alkoxy, or hydroxyl; R 5 is independently selected from H, halogen, or C1-C3 alkoxy; and R 6 is independently selected from H, halogen, hydroxyl, and C1-C3 alkoxy, wherein R 6 is not C1 alkoxy, when R 1 or R 2 is chlorine, R 4 is C1 alkoxy and R 5 is hydrogen; and R 5 is not C1 alkoxy when R 1 or R 2 is chlorine, R 4 is C1 alkoxy, and R 6 is hydrogen. 2. The molecule of claim 1 , wherein R 1 , R 2 , R 5 , or R 6 is independently selected from H, F, Cl, or I. 3. The molecule of claim 1 , wherein R 1 , R 2 , R 5 , or R 6 is independently F. 4. A method of treating prostate cancer comprising administering an effective amount of the compound of claim 1 to a subject having prostate cancer.
Assignees
Inventors
Classifications
- A61K31/4184Primary
condensed with carbocyclic rings, e.g. benzimidazoles · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
Sulfur atoms · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10322113B2 cover?
- Embodiments of the current invention include methods and compositions for regulating the activity of hormone receptors.
- Who is the assignee on this patent?
- Cox Marc, Cherkasov Artem, Univ Texas, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification A61K31/4184. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jun 18 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).